For the first time, Europe's largest drugs company, GSK, is starting the registration process for a vaccine from which it never expects to make money.Globorix will only be used in Africa to prevent meningitis at prices that may never cover its research costs.Experts say it is a sign big companies are changing their business practices, but some critics say it is not enough.Millions of people in Africa are at risk from meningitis, which can kill a child in six hours.
Source BBC NEWS